Copyright
©2011 Baishideng Publishing Group Co.
World J Clin Oncol. May 10, 2011; 2(5): 229-236
Published online May 10, 2011. doi: 10.5306/wjco.v2.i5.229
Published online May 10, 2011. doi: 10.5306/wjco.v2.i5.229
Figure 1 Schema of the metabolic pathway of glucose and 18-F-fluorodeoxyglucose in cells.
fluorodeoxyglucose has the same pathway as glucose up to the phosphorylation process, and does not progress further. Most malignant cells are known to have overexpression of the glucose transporter (*) and low activity of phosphatase(**).
- Citation: Murakami K. FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations. World J Clin Oncol 2011; 2(5): 229-236
- URL: https://www.wjgnet.com/2218-4333/full/v2/i5/229.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i5.229